Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Type of study
Language
Affiliation country
Publication year range
1.
Drugs Aging ; 20(2): 85-100, 2003.
Article in English | MEDLINE | ID: mdl-12534310

ABSTRACT

Periods of intense hormonal fluctuations have been associated with heightened prevalence and exacerbation of underlying psychiatric illness, particularly the occurrence of premenstrual dysphoria, puerperal depression and depressive symptoms during perimenopause. It has been speculated that sex steroids such as estrogens, progestogens, testosterone and dehydroepiandrosterone (DHEA) exert a significant modulation of brain functioning, possibly through interactions with various neurotransmitter systems. It is therefore intuitive that abrupt alterations of these hormones would interfere with mood and behaviour. On the other hand, accumulating data suggest that hormonal interventions may also promote relief or even remission of depressive symptoms, as already demonstrated in studies with patients experiencing postpartum depression and perimenopausal depressive disorders. The extent to which perimenopause, alone, may increase the risk for depression is unclear. However, existing data strongly suggest that some women are particularly vulnerable to developing significant physical and psychological disturbances when entering perimenopause. This article reviews the effect of sex hormones and selective estrogen receptor modulators (SERMs) on mood among peri- and postmenopausal women. There are preliminary, though promising, data on the use of estradiol (particularly transdermal estradiol) to alleviate depression during perimenopause, use of a combination of estrogens and selective serotonin reuptake inhibitors for depression during the postmenopausal period, and the use of testosterone to improve psychological well-being and increase libido among women with induced menopause. Further studies would help to better delineate the usage of hormones as an antidepressant strategy (monotherapy or augmenting treatment) for peri- and postmenopausal women. A brief review of some nonhormonal interventions for the treatment of menopause-related symptoms that may significantly affect a woman's quality of life is also presented. There are some preliminary data suggesting the efficacy of antidepressants for the treatment of hot flushes; existing data on diet supplements and herbal products have shown more mixed results.


Subject(s)
Affect/drug effects , Gonadal Steroid Hormones/therapeutic use , Menopause/psychology , Selective Estrogen Receptor Modulators/therapeutic use , Antidepressive Agents/therapeutic use , Brain/drug effects , Brain/physiology , Depressive Disorder/drug therapy , Depressive Disorder/prevention & control , Drug Therapy, Combination , Female , Gonadal Steroid Hormones/pharmacology , Humans , Menopause/physiology , Premenopause/physiology , Premenopause/psychology , Quality of Life , Selective Estrogen Receptor Modulators/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL